Automated Q:1 Insulin Delivery: Benefits, Challenges, and Q:2 Recommendations Q:3 . A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
View / Open Files
Authors
Jennifer, Sherr
Lutz, Heinemann
Alexander, Fleming
Richard, Bergenstal
Daniela, Bruttomesso
Helene, Hanaire
Reinhard, Holl
John, Petrie
Anne, Peters
Journal Title
Diabetes Care
ISSN
0149-5992
Publisher
American Diabetes Association
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Evans, M., Jennifer, S., Lutz, H., Alexander, F., Richard, B., Daniela, B., Helene, H., et al. Automated Q:1 Insulin Delivery: Benefits, Challenges, and Q:2 Recommendations Q:3 . A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care https://doi.org/10.17863/CAM.85446
Abstract
A technological solution for the management of diabetes in people who require
intensive insulin therapy has been sought for decades. The last 10 years have
seen substantial growth in devices that can be integrated into clinical care. Driven
by the availability of reliable systems for continuous glucose monitoring, we
have entered an era in which insulin delivery through insulin pumps can be modulated
based on sensor glucose data. Over the past few years, regulatory approval
of the first automated insulin delivery (AID) systems has been granted,
and these systems have been adopted into clinical care. Additionally, a community
of persons living with type 1 diabetes has created its own systems using a
do-it-yourself approach by using products commercialized for independent use.
With several AID systems in development, some of which are anticipated to be
granted regulatory approval in the near future, the joint Diabetes Technology
Working Group of the European Association for the Study of Diabetes and the
American Diabetes Association has created this consensus report. We provide a
review of the current landscape of AID systems, with a particular focus on their
safety. We conclude with a series of recommended targeted actions. This is the
fourth in a series of reports issued by this working group. The working group was
jointly commissioned by the executives of both organizations to write the first
statement on insulin pumps, which was published in 2015. The original authoring
group was comprised by three nominated members of the American Diabetes Association
and three nominated members of the European Association for the
Study of Diabetes. Additional authors have been added to the group to increase
diversity and range of expertise. Each organization has provided a similar internal
review process for each manuscript prior to submission for editorial review
by the two journals. Harmonization of editorial and substantial modifications
has occurred at both levels. It is therefore appropriate to use in the title, as has
been done for Q:4 previous statements: “A Joint Statement of the European Association
for the Study of Diabetes and the American Diabetes Association Diabetes
Technology Working Group.” The members of the group have selected the subject
of each statement and submitted the selection to both organizations for
confirmation.
Embargo Lift Date
2025-06-13
Identifiers
This record's DOI: https://doi.org/10.17863/CAM.85446
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338037
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.